Risperidone in the treatment of conduct disorder in preschool children without intellectual disability

Child and Adolescent Psychiatry and Mental Health

Volumn 5, Issue , 2011, Pages

  Ercan, Eyup S ^a   Basay, Burge K ^a   Basay, Omer ^a   Durak, Sibel ^b   Ozbaran, Burcu ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b DR BEHÇET UZ CHILDREN'S HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; RISPERIDONE;

ARTICLE; BEHAVIOR DISORDER; CHILD; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CONDUCT DISORDER; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERPROLACTINEMIA; INTELLECTUAL IMPAIRMENT; MALE; MOTOR DYSFUNCTION; NAUSEA; NECK PAIN; NEUROLOGICAL COMPLICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SEDATION; SIDE EFFECT; VOMITING;

EID: 79953852879     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-5-10     Document Type: Article

References (61)

1. Steiner H. Practice parameters for the assessment and treatment of children and adolescents with conduct disorder. AACAP J Am Acad Child Adolesc Psychiatry 1997, 36(Suppl 10):122-139.
2. Kazdin A. Treatment of Antisocial behavior in Children and Adolescents. 1985, Homewood, Illinois; Dorsey Press.
3. Joseph MR, Walter G, Soutullo CA. Oppositional Defiant and Conduct Disorders. Lewis's Child and Adolescent Psychiatry: Comprehensive Textbook 2007, Philadelphia: Lippincott Williams and Wilkins, Martin A, Volkmar FR, 4.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, DSM-IV-TR 2000, Washington, DC: American Psychiatric Association, 4, American Psychiatric Association.
5. Lahey BB, Loeber R, Burke J, Rathouz PJ. Adolescent outcomes of childhood conduct disorder among clinic-referred boys: Predictors of improvement. J Abnorm Child Psychol 2002, 30(4):333-348. 10.1023/A:1015761723226, 12108765.
6. Christopher RT. Disruptive Behavior Disorders. Kaplan and Saddock's Comprehensive Textbook of Psychiatry 2005, Philadelphia: Lippincott Williams and Wilkins, Sadock B, Sadok VA, 8.
7. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. The Risperidone Conduct Study Group: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQ's. J Am Acad Child Adolesc Psychiatry 2002, 41(9):1026-1036. 10.1097/00004583-200209000-00002, 12218423.
8. Burke D, Loeber R, Birmaher B. Oppositional defiant disorder and conduct disorder: A review of the past 10 years, Part II. J Am Acad Child Adolesc Psychiatry 2002, 41(11):1275-1293. 10.1097/00004583-200211000-00009, 12410070.
9. Wakschlag LS, Leventhal BL, Thomas JM, . with commentary by Pine D Disruptive Behavior Disorders & ADHD in Preschool Children: Characterizing Heterotypic Continuities for a Developmentally-Informed Nosology for DSM-V. Age and Gender Considerations in Psychiatric Diagnosis: A Research Agenda for DSM-V Washington DC: American Psychiatric Publishing Inc, Regier D, First M, Narrow W, with commentary by Pine D.
10. Keenan K, Wakschlag LS. Can a Valid Diagnosis of Disruptive Behavior Disorder Be Made in Preschool Children?. Am J Psychiatry 2002, 159:351-358. 10.1176/appi.ajp.159.3.351, 11869995.
11. Campbell SB. Behavior Problems in Preschool Children: Clinical and Developmental Issues. New York, Guilford 2002,
12. Anders T. Clinical syndromes, relationship disturbances and their assessment, in Relationship Disturbances in Early Childhood: A Developmental Approach. 1989, 25-144. New York, Basic Books, Sameroff A, Emde R.
13. Kochanska G, Murray KT, Coy KC. Inhibitory control as a contributor to conscience in childhood: from toddler to early school age. Child Dev 1997, 68:263-277. 10.2307/1131849, 9180001.
14. Kim-Cohen J, Arseneault L, Caspi A, Tomas PM, Taylor A, Moffitt TE. Validity of DSM-IV conduct disorder in 4 1/2-5-year-old children: a longitudinal epidemiological study. Am J Psychiatry 2005, 162:1108-1117. 10.1176/appi.ajp.162.6.1108, 15930059.
15. Keenan K, Wakschlag LS. Are Oppositional Defiant and Conduct Disorder Symptoms Normative Behaviors in Preschoolers? A Comparison of Referred and Nonreferred Children. Am J Psychiatry 2004, 161(2):356-358. 10.1176/appi.ajp.161.2.356, 14754786.
16. Kim-Cohen J, Arseneault PL, Newcom R, Adams F, Bolton H, Cant L, Delgado K, Freeman J, Golaszewski A, Kelesidi K, Matthew K, Mountain N, Oxley D, Watson S, Werts H, Caspi A, Moffitt TE. Five-year predictive validity of DSM-IV conduct disorder research diagnosis in 41/2-5-year-old children. Eur Child Adolesc Psychiatry 2009, 18:284-29. 10.1007/s00787-008-0729-1, 19165535.
17. Rowe R, Maughan B, Pickles A, Costello EJ, Angold A. The relationship between DSM-IV oppositional defiant disorder and conduct disorder: findings from the Great Smoky Mountains Study. J Child Psychol Psychiatry 2002, 43:365-373. 10.1111/1469-7610.00027, 11944878.
18. Olds DL, Henderson CR, Cole R, Eckenrode J, Kitzman H, Luckey D, Pettitt L, Sidora K, Morris P, Powers J. Long-term effects of nurse home visitation on children's criminal and antisocial behavior: 15-year follow-up of a randomized controlled trial. JAMA 1998, 280:1238-1244. 10.1001/jama.280.14.1238, 9786373.
19. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Risperidone Disruptive Behavior Study Group: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002, 159:1337-1346. 10.1176/appi.ajp.159.8.1337, 12153826.
20. Pandina G, Aman M, Findling R. Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol 2006, 16(4):379-392. 10.1089/cap.2006.16.379, 16958564.
21. Moretti MM, Emmrys C, Grizenko N, Holland R, Moore K, Shamsie J, Hamilton H. The treatment of conduct disorder: Perspectives from across Canada. Can J Psychiatry 1997, 42:637-648.
22. Kazdin AE. Parent management training: Evidence, outcomes and issues. J Am Acad Child Adolesc Psychiatry 1997, 39:414-420.
23. Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S. International consensus statement on attentin deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs): Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004, 14:11-28. 10.1016/S0924-977X(03)00045-2, 14659983.
24. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumjer JL. A double blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000, 39(4):509-516. 10.1097/00004583-200004000-00021, 10761354.
25. Ipser J, Stein DJ. Systemic review of pharmacotherapy of disruptive behavior disorders in children and adolescents. Psychopharmacology 2007, 191:127-140. 10.1007/s00213-006-0537-6, 16983542.
26. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameters for the use of stimulant medications in the treatment of children, adolescents, and adults. AACAP J Am Acad Child Adolesc Psychiatry 2002, 41(2 Suppl):26-49.
27. Günther T, Herpertz-Dahlmann B, Jolles J, Konrad K. The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder. J Child Adolesc Psychopharmacol 2006, 16(6):725-735.
28. Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS. Pharmacotherapy of agression in children and adolescents: Efficacy and effect size. J Can Acad Child Adolesc Psychiatry 2006, 15(1):27-39. 2277275, 18392193.
29. Turgay A, Binder C, Synder R, Fisman S. Long-term safety and efficacy of risperdone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002, 110:e34. 10.1542/peds.110.3.e34, 12205284.
30. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B, . the Risperidone Disruptive Behavior Study Group Long-term, open-label study of risperidone in children with severe disruptive behavior disorders and below-average IQ. Am J Psychiatry 2004, 161:677-684. 10.1176/appi.ajp.161.4.677, 15056514, the Risperidone Disruptive Behavior Study Group.
31. Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S. Risperidone Disruptive Behavior Study Group: Risperidone in children with disruptive behavior disorders and subaverage intelligence: A 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 2005, 44:64-72. 10.1097/01.chi.0000145805.24274.09, 15608545.
32. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006, 163:402-410. 10.1176/appi.ajp.163.3.402, 16513860.
33. Aman M, Buitelaar J, De Smedt G, Wapenaar R, Binder C. Pharmacotherapy of disruptive behavior and item changes on a standardized rating scale: Pooled analysis of risperidone effects in children with subaverage IQ. J Child Adolesc Psychopharmacol 2005, 15(2):220-232. 10.1089/cap.2005.15.220, 15910206.
34. Biederman J, Mick E, Wozniak J, Aleardi M, Spencer T, Faraone SV. An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2005, 15(2):311-317. 10.1089/cap.2005.15.311, 15910215.
35. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencet TJ, Kim GS, Shapiro S. Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. J Am Acad Child Adolesc Psychiatry 1999, 38:960-965. 10.1097/00004583-199908000-00011, 10434487.
36. Research Units of Pediatric Psychopharmacology (RUPP) Autism Network Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002, 347:314-321. 10.1056/NEJMoa013171, 12151468, Research Units of Pediatric Psychopharmacology (RUPP) Autism Network.
37. Research Units of Pediatric Psychopharmacology (RUPP) Autism Network Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after six months. Am J Psychiatry 2005, 162:1361-69. 10.1176/appi.ajp.162.7.1361, 15994720, Research Units of Pediatric Psychopharmacology (RUPP) Autism Network.
38. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114(5):e634-641. 10.1542/peds.2003-0264-F, 15492353.
39. Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, Spitznagel E. Risperdione in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. J Child Adolesc Psychopaharmacology 2006, 16(5):575-587.
40. Gleason MM, et al. Psychopharmacological Treatment for Very Young Children: Contexts and Guidelines. J Am Acad Child Adolesc Psychiatry 2007, 46(12):1532-1572. 10.1097/chi.0b013e3181570d9e, 18030077.
41. Connor DF, Glatt SJ, Lopez I. Psychopharmacology and aggression: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 2002, 41:253-261. 10.1097/00004583-200203000-00004, 11886019.
42. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry 2005, 58:589-594. 10.1016/j.biopsych.2005.03.019, 16239162.
43. Masi G, Cosenza A, Mucci M, De Vito G. Risperidone monotherapy in preschool children with pervasive developmental disorders. J Child Neurol 2001, 16(6):395-400.
44. Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003, 64(9):1039-1047. 10.4088/JCP.v64n0909, 14628979.
45. Cesena M, Gonzalez-Heydrich J, Szigethy E, Kohlenberg TM, DeMaso DR. Case Report: A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol 2002, 12(4):337-345. 10.1089/104454602762599880, 12625994.
46. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997, 36:980-988. 10.1097/00004583-199707000-00021, 9204677.
47. Gokler B, Unal F, Pehlivanturk B, Cengel Kultur E, Akdemir D, Taner Y. Reliability and vali{dotless}di{dotless}ty of Schedule for Affective Disorders and Schizophrenia for School-age Children-Present and Lifetime Version-Turkish Version (K-SADS-PL-T) [in Turkish]. Cocuk ve Genclik Ruh Sagli{dotless}ǧi{dotless} Dergisi (Turkish Journal of Child and Adolescent Mental Health) 2004, 11(3).
48. Birmaher B, et al. Schedule for affective disorders and schizophrenia for school-age children (K-SADS-PL) for the assessment of preschool children - A preliminary psychometric study. J Psychiatr Res 2009, 43(7):680-686. 10.1016/j.jpsychires.2008.10.003, 2736874, 19000625.
49. Egger HL, Erkanli A, Keeler G, Potts E, Walter BK, Angold A. Test-retest reliability of the preschool age psychiatric assessment (PAPA). J Am Acad Child Adolesc Psychiatry 2006, 45(5):538-49. 10.1097/01.chi.0000205705.71194.b8, 16601400.
50. Holmes S, Slaughter JR, Kashani J. Risk Factors in Childhood That Lead to the Development of Conduct Disorder and Antisocial Personality Disorder. Child Psychiatry Hum Dev 2001, 31(3). 10.1023/A:1026425304480, 11196010.
51. Ercan ES, Aydi{dotless}n C. Dikkat Eksikligi Hiperaktivite Bozuklugu. Istanbul, Gendas, Yayi{dotless}nevi. 1999, [Attention Deficit Hyperactivity Disorder, Istanbul, Gendas Publications].
52. Barkley RA. Managing the Defiant Child: A Guide to Parent Training. 1997, New York, Guilford Press.
53. Savasi{dotless}r I, Sezgin N, Erol N. Ankara Developmental Screening Inventory [in Turkish]. 1993, Ankara, Turk Psikologlar Dernegi (Turkish Psychological Association), 2.
54. National Institute of Mental Health Clinic Global Impressions Scale (CGI). Psychopharmacol Bull 21:839-843. National Institute of Mental Health.
55. Turgay A. Disruptive Behavior Disorders Child and Adolescent Screening and Rating Scales for Children, Adolescents, Parents and Teachers. West Bloomfield (Michigan), Integrative Therapy Institute Publication 1994,
56. Ercan ES, Amado S, Somer O, Çi{dotless}koǧlu S. Development of a test battery for the assessment of attention deficit hyperactivity disorder [in Turkish]. Cocuk ve Genclik Ruh Sagli{dotless}ǧi{dotless} Dergisi (Turkish Journal of Child and Adolescent Mental Health) 2001, 8:132-144.
57. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The extrapyramidal symptom rating scale. Can J Neurol Sci 1980, 7:233.
58. Ercan ES, Kutlu A, Ci{dotless}koglu S, Veznedaroglu B, Erermis S, Varan A. Risperidone in children and adolescents with conduct disorder: Asingle-center, open-label study. Curr Ther Res Clin Exp 2003, 64(1):55-64.
59. Masi G, Cosenza A, Mucci M. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 2001, 11(4):389-394. 10.1089/104454601317261564, 11838821.
60. Dunbar F, Kusumakar V, Daneman D, Schulz M. Growth and sexual maturation during long term treatment with risperidone. Am J Psychiatry 2004, 161:918-920. 10.1176/appi.ajp.161.5.918, 15121661.
61. Erdogan A, Atasoy N, Akkurt H, Ozturk D, Karaahmet E, Yalug I, Yalug K, Ankarali H, Balciolu I. Risperidone and liver function tests in children and adolescents: A short-term prospective study. Prog Neuropychopharmacol Biol Psychiatry 2008, 32(3):849-57.